Nobody said it should be $20 at this point ... 'If these problems get cleared up and Amarin gets the 35 mil man cohort the stock will go to $20 plus'
Regarding sales force:
'We remind investors that on November 19, 2013, Pozen announced that Vimovo commercialization partner, AstraZeneca AB, has entered into an agreement with Horizon Pharma USA whereby Horizon acquired the U.S. rights for Vimovo.'
'As a result of the acquisition of the U.S. rights to Vimovo, Horizon began the expansion of its sales force to approximately 250 primary care representatives and 40 rheumatology sales specialists. The company completed the hiring and training of the expanded sales force in January 2014 and began full promotion of Vimovo in early February 2014.'
'After all, 2013 U.S. Vimovo royalties totaled only $2.1 million on sales of $21 million. Well, based on the breakdown of royalties in the first quarter alone, Horizon will crush that $5 million minimum payment by the end of the second quarter. For 2014, we think it is likely that Horizon does over $100 million in Vimovo sales, putting Pozen's royalty at greater than $10 million from U.S. sales alone'
Market Data 
Markets 
AI
